Clinical drug investigation
Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin® in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cancer.
Qianqian Hong, Yuhuan Jiao, Dongyang Li, Hongyun Ma, Kun Wu, Liangzhi Xie
Published: 202610.1007/s40261-025-01518-8
Abstract
BACKGROUND: SCT510 is a proposed biosimilar of bevacizumab (Avastin®), a monoclonal antibody that targets vascular endothelial growth factor. OBJECTIVE: This analysis aimed to characterize the population pharmacokinetics of SCT510, a bevacizumab bios…
Preview only. Read the full abstract at the source